TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06359275
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine，1000mg/m2，IV，D1，8，Q3W
Study: NCT05995769
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Study: NCT04416750
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with Imatinib
Study: NCT04464005
Drug: Magnesium sulfate 33% solution
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
Study: NCT00003514
Drug: antineoplaston A10
Normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003514
Drug: antineoplaston AS2-1
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053339
Drug: tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053339
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05048784
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT06433869
Drug: serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.
Study: NCT06433869
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.
Study: NCT05061771
Drug: nomacopan (rVA576)
Normalized name: Nomacopan
DrugBank: Nomacopan (DB14991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomacopan an inhibitor of complement C5 and LTB4
Study: NCT00096850
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
Study: NCT00096850
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
Study: NCT00096850
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
Study: NCT04915287
Drug: Avatrombopag maleate
Normalized name: AVATROMBOPAG MALEATE
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure
Study: NCT05108935
Drug: Suboxone
Normalized name: Suboxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT05108935
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT05108935
Drug: Mavyret
Normalized name: Mavyret
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study: NCT06211478
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
Study: NCT06660667
Drug: Diluent
Normalized name: Diluent
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
Study: NCT06548867
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.
Study: NCT05908513
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
Study: NCT04980170
Drug: Amoxicillin with Clavulanic Acid 635mg
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
Study: NCT06359015
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
Study: NCT06359015
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
Study: NCT05583409
Drug: Osimertinib 80 MG
Normalized name: osimertinib 80 MG
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 80mg, po, Qd
Study: NCT04555291
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
Study: NCT04915287
Drug: Medicine
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
Study: NCT05499065
Drug: Cetuximab-IRDye800
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
Study: NCT04995354
Drug: EGF loaded Hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
Study: NCT00000698
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04840927
Drug: E7386
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regimen A: 40 milligram (mg) IR Oral Tablet.
Study: NCT05130177
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
Study: NCT05130177
Drug: Domvanalimab
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
Study: NCT05288075
Drug: Indacaterol/glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.
Study: NCT05627960
Drug: AG-01 Compound
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.
Study: NCT05519410
Drug: Sintilimab and Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
Study: NCT04628663
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration
Study: NCT05755854
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
Study: NCT05909696
Drug: rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advanced intravenous injection of rocuronium before the succinylcholine injection
Study: NCT05390255
Drug: Mometasone furoate nasal spray hormone
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
Study: NCT05390255
Drug: Mometasone furoate nasal spray hormone + oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Mometasone (DB00764)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
Study: NCT05390255
Drug: Mometasone furoate nasal spray hormone + omalizumab
Normalized name: mometasone furoate Nasal Spray
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
Study: NCT00002160
Drug: Ziconotide
Normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04702789
Drug: Dorzolamide-timolol-brimonidine and latanoprost
Normalized name: dorzolamide / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Study: NCT04702789
Drug: Dorzolamide-timolol and latanoprost
Normalized name: dorzolamide / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Study: NCT05294367
Drug: Magnesium Chloride-based Lotion
Normalized name: Magnesium Chloride
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given topically
Study: NCT05892887
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
Study: NCT06369935
Drug: Equecabtagene Autoleucel
Normalized name: Equecabtagene autoleucel
DrugBank: Equecabtagene autoleucel (DB19016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
Study: NCT06520683
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Tislelizumab 200mg (day 1 and day 22), administered after surgery
Study: NCT04669457
Drug: Intra-nasal Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
Study: NCT04669457
Drug: Oral Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
Study: NCT00517972
Drug: Omacor (omega-3-acid ethyl esters)
Normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05965908
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: glucagon-like peptide 1 receptor agonist
Study: NCT05965908
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: biguanide antihyperglycemic
Study: NCT05741632
Drug: Moxifloxacin Ophthalmic Solution
Normalized name: Moxifloxacin Ophthalmic Solution
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
Study: NCT05741632
Drug: Levofloxacin Ophthalmic
Normalized name: Levofloxacin Ophthalmic
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
Study: NCT04876716
Drug: Azole
Normalized name: Azole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing according to the SPC
Study: NCT04876716
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200mg loading dose on day 1 and 100mg QD thereafter
Study: NCT06123754
Drug: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
Study: NCT05261269
Drug: DAN-222
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV every week to subjects
Study: NCT05261269
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally once daily
Study: NCT06123754
Drug: placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
Study: NCT04938232
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT04938232
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT00215384
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06140927
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
Study: NCT06391450
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT06358963
Drug: Receive 30 mg of Coq10
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Study: NCT04547179
Drug: Fremanezumab-Vfrm
Normalized name: fremanezumab-vfrm
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
Study: NCT05123053
Drug: Amifampridine
Normalized name: Amifampridine
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg tablet
Study: NCT05884970
Drug: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz
Normalized name: salbutamol and budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
Study: NCT05884970
Drug: 100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK
Normalized name: salbutamol and budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
Study: NCT05884970
Drug: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz
Normalized name: salbutamol and budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
Study: NCT04729101
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT04729101
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00000645
Drug: Hypericin
Normalized name: Hypericin
DrugBank: Hypericin (DB13014)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06200376
Drug: T3011
Normalized name: T3011
DrugBank: MVR-T3011 (DB17378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3011 will be administered intraperitoneally twice a week.
Study: NCT04876924
Drug: BBP-711
Normalized name: BBP-711
DrugBank: BBP-711 (DB18199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBP-711, oral suspension
Study: NCT05863832
Drug: Ciprofloxacin Tablets & Metronidazole tablets
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofolxacin 500 mg + Metronidazole 500 mg
Study: NCT06659991
Drug: alcohol condition
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol
Study: NCT05281471
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered according to local practice
Study: NCT05281471
Drug: Bevacizumab (or biosimilar)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered according to local practice
Study: NCT05470348
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05434091
Drug: PF-07291177
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
Study: NCT05452213
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion.
Study: NCT05049603
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
Study: NCT05717374
Drug: caudal block using dexamethasone
Normalized name: Ivy Block
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
Study: NCT05253053
Drug: TT-00420
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00420 tablet will be administered orally once daily per protocol defined schedule.
Study: NCT05253053
Drug: Combination Product: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
Study: NCT05253053
Drug: Combination Product: Nab-Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
Study: NCT04080895
Drug: Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
Study: NCT04080895
Drug: Artemether-lumefantrine + Amodiaquine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2